Bacterial Resistance to Antimicrobial Agents¶
Chapter 150 | Part 5: Infectious Diseases
KEY CLINICAL POINTS¶
- Resistance mechanisms include target alteration, reduced drug access, and drug modification.
- β -Lactamases are the most common resistance mechanism, with ESBLs and carbapenemases driving multidrug resistance.
- Antimicrobial stewardship and infection control are critical to mitigating resistance spread.
1. DEFINITION & OVERVIEW¶
Resistance refers to reduced antimicrobial activity due to bacterial mechanisms. Resistance mechanisms include target modification, reduced drug access, and drug inactivation. Resistance can be intrinsic (chromosomal) or acquired (plasmid-mediated).
Table 150-1: Common Resistance Mechanisms¶
| ANTIBACTERIAL AGENT(S) | MAJOR TARGET | MECHANISM(S) OF ACTION | MECHANISM(S) OF RESISTANCE |
|---|---|---|---|
| b-Lactams | Cell-wall synthesis | Bind PBPs | b-Lactamases, altered PBPs, reduced porin diffusion |
| Glycopeptides | Cell-wall synthesis | Block glycosyltransferases | Altered d-Ala-d-Ala targets |
| Aminoglycosides | Protein synthesis | Bind 30S ribosome | Drug-modifying enzymes, efflux pumps |
| Macrolides | Protein synthesis | Bind 50S ribosome | Ribosomal methylation, efflux pumps |
| Quinolones | DNA synthesis | Inhibit DNA gyrase/topoisomerase IV | Altered targets, efflux |
1.1 Resistance Mechanisms¶
Three categories: (1) Target alteration (e.g., PBPs in β -lactams), (2) Reduced access (porin channels, efflux pumps), (3) Drug modification (enzymes like β -lactamases).
1.2 β -Lactam Resistance¶
β -Lactamases degrade β -lactams; ESBLs and carbapenemases (e.g., KPCs, NDMs) confer resistance to multiple agents. AmpC enzymes are chromosomally encoded and inducible.
2. EPIDEMIOLOGY¶
Resistance prevalence varies geographically. CDC 2019 report highlights urgent threats like carbapenem-resistant Enterobacterales and drug-resistant N. gonorrhoeae. Transmission via healthcare workers and environmental reservoirs amplifies resistance.
Table 150-2: Antibiotic Resistance Threats¶
| THREAT CATEGORY | ORGANISMS |
|---|---|
| Urgent | Carbapenem-resistant Acinetobacter, C. difficile, Carbapenem-resistant Enterobacterales |
| Urgent | Drug-resistant N. gonorrhoeae, Drug-resistant S. aureus |
| Watch List | Azole-resistant A. fumigatus, Drug-resistant M. tuberculosis |
2.1 Resistance Reservoirs¶
Environmental and clinical settings contribute to resistance reservoirs. Prior antibiotic use, hospitalization, and infection with resistant pathogens increase individual risk.
2.2 CDC Threats (2019)¶
Urgent threats include carbapenem-resistant Acinetobacter, C. difficile, and drug-resistant N. gonorrhoeae. Watch-list threats involve azole-resistant Aspergillus and multidrug-resistant P. aeruginosa.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Resistance arises from mutations, plasmid acquisition, or gene transfer. β -Lactamases (ESBLs, carbapenemases) and efflux pumps are key drivers. Chromosomal mutations alter targets (e.g., PBPs in β -lactams).
3.1 β -Lactam Resistance¶
ESBLs (e.g., KPCs, OXA-48) degrade penicillins and cephalosporins. Carbapenemases (e.g., NDMs) resist carbapenems. AmpC enzymes are inducible and degrade cephalosporins.
3.2 Other Mechanisms¶
Aminoglycoside resistance via 16S rRNA methylation (e.g., Erm methylases). Macrolide resistance via ribosomal mutations (e.g., 23S rRNA mutations).
4. CLINICAL FEATURES¶
Clinical manifestations depend on resistant pathogens. C. difficile infections are linked to antibiotic use, not direct resistance. Multidrug-resistant organisms (MDROs) complicate treatment with limited therapeutic options.
4.1 C. difficile¶
Spore-forming, spreads via contaminated surfaces. Linked to antibiotic-induced microbiome disruption. Pseudomembranous colitis and severe diarrhea.
4.2 MDROs¶
Carbapenem-resistant Enterobacterales (CRE) and Acinetobacter spp. cause severe infections with high mortality. Treatment options are limited.
5. DIFFERENTIAL DIAGNOSIS¶
Differential includes resistant pathogens (e.g., MRSA, VRE) and non-resistant infections. Consider C. difficile in antibiotic-associated diarrhea. Use microbiological testing to distinguish resistance from other causes.
5.1 Common Resistant Pathogens¶
MRSA, VRE, CRE, drug-resistant N. gonorrhoeae, and C. difficile. Differentiate from non-resistant infections via susceptibility testing.
6. INVESTIGATIONS & DIAGNOSIS¶
MIC testing determines susceptibility. Molecular methods (e.g., PCR) detect resistance genes (e.g., mcr-1, blaKPC). Rapid diagnostics aid in selecting appropriate agents.
6.1 MIC Testing¶
Interpretation based on breakpoints (susceptible, intermediate, resistant). MIC values correlate with pharmacokinetics and clinical outcomes.
6.2 Molecular Testing¶
PCR detects resistance genes (e.g., mcr-1, blaNDM, blaKPC). Useful for rapid identification of carbapenemases and other resistance mechanisms.
7. MANAGEMENT & TREATMENT¶
Combination therapy and β -lactamase inhibitors (e.g., clavulanate, avibactam) enhance efficacy. Stewardship programs and infection control reduce resistance spread.
7.1 β -Lactamase Inhibitors¶
Clavulanate, sulbactam, avibactam, vaborbactam inhibit ESBLs and carbapenemases. Used with β -lactams (e.g., amoxicillin-clavulanate, meropenem-vaborbactam).
7.2 Stewardship¶
Optimize antimicrobial use duration and selection. Reduce unnecessary prescriptions and prevent resistance transmission via infection control.
8. PROGNOSIS & COMPLICATIONS¶
Prognosis worsens with multidrug resistance. Complications include treatment failure, sepsis, and mortality. C. difficile infections can lead to severe colitis and death.
8.1 MDRO Outcomes¶
Higher mortality and treatment failure. Limited therapeutic options increase morbidity and mortality in critical infections.
9. SPECIAL CONSIDERATIONS¶
Pregnancy, pediatrics, and elderly populations require careful antimicrobial selection. Neonatal infections and immunocompromised hosts face unique challenges with resistance.
9.1 Neonatal Infections¶
Limited drug penetration and increased risk of resistance. Prioritize agents with proven safety (e.g., ampicillin, gentamicin).
10. KEY POINTS & CLINICAL PEARLS¶
- Resistance mechanisms include target alteration, reduced access, and drug modification. 2. ESBLs and carbapenemases drive multidrug resistance. 3. Antimicrobial stewardship and infection control are critical to mitigating resistance. 4. Rapid diagnostics and combination therapy improve outcomes for MDRO infections.